Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial
Not available.
Saved in:
| Main Authors: | Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa Rimsza, Ahmad Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher Carlson, Joo Y. Song |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-07-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12159 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model.
by: Thaiz F Borin, et al.
Published: (2017-01-01) -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
by: Giuseppe Rossi, et al.
Published: (2016-11-01) -
Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues
by: KD Kaplanov, et al.
Published: (2019-03-01) -
Managing Follicular Lymphoma in the Elderly Population
by: Jiao Jie Cherie Tan, et al.
Published: (2023-01-01) -
Follicular Lymphoma Presenting with Leptomeningeal Disease
by: Rubens Costa, et al.
Published: (2014-01-01)